Algeta ASA : Algeta to Participate in Upcoming Investor Conferences

     Algeta ASA : Algeta to Participate in Upcoming Investor Conferences

Oslo, Norway, 20 February 2013 - Algeta ASA (OSE: ALGETA), a company focused
on the development of novel targeted cancer therapeutics, announces that
members of its senior management team will participate in the following
upcoming investor conferences:

Citi Global Healthcare Conference 2013
 Date: 25-27 February 2013
 Participants:
              Jeff Albers (President, Algeta US)
              Mike Booth (IR)
 Panel date & time: Tuesday 25 February, 2013, 10:20am EST
 Venue: New York, NY, USA

Credit Suisse Global Healthcare One-on-One Conference
          Date: 5-6 March 2013
          Participants:
                  Andrew Kay (President & CEO)
                  Oystein Soug (CFO)
                  Mike Booth (IR)
          Venue: London, UK

Carnegie Nordic Healthcare Seminar
 Date: 12 March 2013
 Participants:
                    Thomas Ramdahl (EVP & CTO)
                    Renate Birkeli (IR)
 Presentation date & time: Tuesday 12 March, 2013, 10:05am CET
 Venue: Stockholm, Sweden

Presentations,  where   applicable,  will   be   available  to   download   at 
www.algeta.com following these events.

                                     ###

For further information, please contact:

Mike Booth / Renate Birkeli          +47 23 00 67 32
Communications & Corporate Affairs   ir@algeta.com
Media enquiries:
Mark Swallow                         +44 207 638 9571
Citigate Dewe Rogerson               mark.swallow@citigatedr.co.uk
Knut Ekern                           +47 22 04 82 00
Gambit Hill & Knowlton               knut.ekern@hkstrategies.com
Kari Watson                          +1 781 235 3060
MacDougall Biomedical Communications kwatson@macbiocom.com 
US investor enquiries:
Tricia Swanson                       +1 646 378 2953
The Trout Group                      tswanson@troutgroup.com

About Algeta

Algeta is a company focused on developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform. The Company
is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,
based in Cambridge, MA performing commercial marketing operations in the US.
Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more
information please visit www.algeta.com.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
HUG#1679229
 
Press spacebar to pause and continue. Press esc to stop.